Monitoring of Cytomegalovirus Reactivation in Bone Marrow Transplant Recipients by Real-time PCR
Cytomegalovirus (CMV) has been recognized as the most important viral pathogen in persons undergoing bone marrow transplantation (BMT). The aim was to develop a quantitative PCR assay to quantify CMV DNA in peripheral blood leukocytes (PBLs) of bone marrow transplantation (BMT) patients. An in-house real-time PCR assay based on TaqMan technology was developed to monitor the quantity of CMV DNA in PBLs of the BMT recipients. Sequential blood samples (415 specimens) were collected from 43 patients as weekly intervals until day 100 after transplantation. The CMV DNA was quantified in parallel with the pp65 antigenemia assay in PBL samples. Viral reactivation occurred in 51% and 41.8% of the recipients as detected by RQ-PCR and antigenemia assays respectively. There was a significant correlation between both assays (P < 0.0001); however, the RQ-PCR was more sensitive than the antigenemia. CMV DNA was detected by the RQ-PCR by a median of 14 days earlier than the antigenemia. Preemptive therapy was implemented in the antigenemia positive cases. The administration of ganciclovir led to a rapid decrease in the viral load. After preemptive therapy, the antigenemia achieved a negative result earlier than the RQ-PCR assay (a median of 17.5 days). An increase of viral load in both quantitative assays and of cyclosporine serum level were identified as the most significant risk factors for CMV reactivation. The quantitative CMV PCR might be a useful tool for monitoring the CMV reactivation and guiding the efficacy of the CMV preemptive therapy in BMT recipients.
KeywordsCytomegalovirus Cyclosporine pp65 Antigenemia Real-time PCR TaqMan
This work was supported by grants from Hematology, Oncology and BMT Research Center, Tehran University Medical Sciences. We would like to thank Mr. Chahardouli for assistance in lab and Dr. Shamshiri for assistance in the statistical analysis. We would like to thank all clinicians and nurses who participated and provided material for this study. In particular we acknowledge Drs. Jahani, Mosavi, Bibordi, Bahar, Irvani.
- 5.Winston DJ, Ho WG, Bartoni K et al (1999) Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:179–184Google Scholar
- 11.Boeckh M, Gooley TA, Myerson D et al (1996) Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 10:4063–4071Google Scholar
- 24.Tanabe K, Tokumoto T, Ishikawa N et al (1997) Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 64:1721–1725PubMedCrossRefGoogle Scholar
- 26.Solano C, Munoz I, Gutierrez A et al (2001) Qualitative plasma PCR Assay (AMPLICOR CMV Test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 39:3938–3941PubMedCrossRefGoogle Scholar
- 27.Ljungman P, Plotkin S (1995) Workshop on CMV disease—definitions, clinical severity scores and new syndromes. Scand J Infect Dis Suppl 99:87–89Google Scholar
- 28.Przepiorka D, Weisdorf D, Martin P et al (1994) Consensus conference on Acute GVHD grading. Bone Marrow Transplant 15:825–828Google Scholar
- 45.Pumannova M, Roubalova K, Vitek A, Sajdova J (2006) Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation. Diagn Microbiol Infect Dis 54:115–120PubMedCrossRefGoogle Scholar